<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02448043</url>
  </required_header>
  <id_info>
    <org_study_id>STU00200526</org_study_id>
    <nct_id>NCT02448043</nct_id>
  </id_info>
  <brief_title>Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure</brief_title>
  <official_title>Cutaneous Prostaglandin Application: Nail Growth, Nail Brittleness, and Eye Pressure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Allergan</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Topical prostaglandin agents are used to help reduce eye pressure in glaucoma patients.
      Bimatoprost (Lumigan 0.01%) is such an agent (Allergan, Inc.). Several of our patients on
      bimatoprost and an observational study of patients on bimatoprost in another center reported
      that fingernails grew longer and became less brittle using the topical eye drops to the eyes.
      The purpose of the double-blinded study is to determine whether the application of the eye
      drops directly to the proximal nail fold of one hand using the opposite hand as a control
      will result in longer nails, less brittle nails, and reduced eye pressures should any of the
      medication be absorbed into the systemic circulation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In addition to our observations with topical bimatoprost on fingernail growth, Wand and
      colleagues applied bimatoprost to the base of the fingernails demonstrating a 16.9% increase
      in fingernail growth from baseline, and a 10.4% increase from baseline on untreated nail
      beds. Other than these two reports, there are no studies addressing this topic to our
      knowledge based on a Medline search for off-label use of this drug. Other relevant studies
      have addressed increased hair and eyelash growth with the prostaglandin agents. Researching
      the biochemistry of the relationship of prostaglandins to hair and nail growth, the final
      common pathway appears to be with protein kinase C and the production of tropocollagens. The
      dermatology literature has demonstrated that both hair and nail keratocytes reside in the
      nail bed suggesting that increased collagen production may enhance the growth of both the
      nail bed and nail plate, possibly reducing nail brittleness.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">March 2017</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Nail growth</measure>
    <time_frame>30 days</time_frame>
    <description>Measured by digital calipers</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intraocular pressure effects</measure>
    <time_frame>30 days</time_frame>
    <description>Eye pressures by Goldmann applanation tonometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nail Brittleness</measure>
    <time_frame>30 days</time_frame>
    <description>Subjective assessment by subjects on scale of 1 (no brittleness)- 4 (maximum brittleness.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Nail Growth Cessation</condition>
  <condition>Intraocular Pressure</condition>
  <arm_group>
    <arm_group_label>Bimatoprost 0.01% drops</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Bimatoprost 0.01% drops placed on the proximal nail folds of the randomized hand digits two times per day for 30 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Saline solution drops placed on the proximal nail folds of the hand digits opposite from the study hand two times per day for 30 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bimatoprost 0.01%</intervention_name>
    <description>Bimatoprost drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days</description>
    <arm_group_label>Bimatoprost 0.01% drops</arm_group_label>
    <other_name>Lumigan 0.01%</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>placebo: saline</intervention_name>
    <description>Placebo drops added to the proximal nail folds of the randomized study hand digits two times per day for 30 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  English speaking

          -  Normotensive or glaucoma suspects on no ocular medications

          -  No manicure within 2 weeks of the study.

        Exclusion Criteria:

          -  Individuals on topical or systemic essential fatty acids (EFA's) in hand lotions,
             creams, ointments, or medication, or on biotin.

          -  Digits with signs of nail injury, deformity, or infection.

          -  Nail biters, nail polishers, artificial nail wear or gels, and nail and trimming and
             filing until the study endpoint.

          -  Women of childbearing age who are pregnant or who are trying to become pregnant.

          -  Individuals with allergies or sensitivity to prostaglandin agents.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David J Palmer, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>David J. Palmer, MD</name>
      <address>
        <city>Glenview</city>
        <state>Illinois</state>
        <zip>60026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Weston BC. Migraine headache associated with latanoprost. Arch Ophthalmol. 2001 Feb;119(2):300-1.</citation>
    <PMID>11176999</PMID>
  </reference>
  <reference>
    <citation>Ziboh VA, Miller CC. Essential fatty acids and polyunsaturated fatty acids: significance in cutaneous biology. Annu Rev Nutr. 1990;10:433-50. Review.</citation>
    <PMID>2200473</PMID>
  </reference>
  <results_reference>
    <citation>Khouri AS, Fechtner RD, Zimmerman, TJ. Latanoprost: A New Approach to the Treatment of Glaucoma. Today's Therapeutic Trends 14: 225-240, 1997</citation>
  </results_reference>
  <results_reference>
    <citation>Woodward DF, Krauss AH, Chen J, Lai RK, Spada CS, Burk RM, Andrews SW, Shi L, Liang Y, Kedzie KM, Chen R, Gil DW, Kharlamb A, Archeampong A, Ling J, Madhu C, Ni J, Rix P, Usansky J, Usansky H, Weber A, Welty D, Yang W, Tang-Liu DD, Garst ME, Brar B, Wheeler LA, Kaplan LJ. The pharmacology of bimatoprost (Lumigan). Surv Ophthalmol. 2001 May;45 Suppl 4:S337-45. Review. Erratum in: Surv Ophthalmol 2002 May-Jun;47(3):295.</citation>
    <PMID>11434936</PMID>
  </results_reference>
  <results_reference>
    <citation>Bean GW, Camras CB. Commercially available prostaglandin analogs for the reduction of intraocular pressure: similarities and differences. Surv Ophthalmol. 2008 Nov;53 Suppl1:S69-84. doi: 10.1016/j.survophthal.2008.08.012. Review.</citation>
    <PMID>19038626</PMID>
  </results_reference>
  <results_reference>
    <citation>Sjoquist B. Human pharmacokinetic studies summary. Pharmacia and Upjohn Company Technical Report 9500155. March 25, 1995.</citation>
  </results_reference>
  <results_reference>
    <citation>Tan J, Berke S. Latanoprost-induced prostaglandin-associated periorbitopathy. Optom Vis Sci. 2013 Sep;90(9):e245-7; discussion 1029. doi: 10.1097/OPX.0b013e31829d8dd7.</citation>
    <PMID>23912967</PMID>
  </results_reference>
  <results_reference>
    <citation>Wand M, Shields BM. Cystoid macular edema in the era of ocular hypotensive lipids. Am J Ophthalmol. 2002 Mar;133(3):393-7. Review.</citation>
    <PMID>11915838</PMID>
  </results_reference>
  <results_reference>
    <citation>Cohen JL. Enhancing the growth of natural eyelashes: the mechanism of bimatoprost-induced eyelash growth. Dermatol Surg. 2010 Sep;36(9):1361-71. doi: 10.1111/j.1524-4725.2010.01522.x. Review.</citation>
    <PMID>20384750</PMID>
  </results_reference>
  <results_reference>
    <citation>Johnstone MA. Hypertrichosis and increased pigmentation of eyelashes and adjacent hair in the region of the ipsilateral eyelids of patients treated with unilateral topical latanoprost. Am J Ophthalmol. 1997 Oct;124(4):544-7.</citation>
    <PMID>9323945</PMID>
  </results_reference>
  <results_reference>
    <citation>Wand M. New side effect of Prostaglandins. Agsocietynet@aaoforums.aao.org. Jan 2015.</citation>
  </results_reference>
  <results_reference>
    <citation>Seed Oils and Essential Fatty Acids. Retrieved 5/21/12 http://www.naturopathica.com/system/user_files/attachments/7/original/Naturopathica_Seed_Oils.pdf</citation>
  </results_reference>
  <results_reference>
    <citation>Janis J (ed). Nail bed injuries. Essential of Plastic Surgery: A UT Southwestern Medical Center Handbook. St Louis, MO: Quality Medical Publishing, Inc: 560-567, 2007.</citation>
  </results_reference>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2015</study_first_submitted>
  <study_first_submitted_qc>May 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 19, 2015</study_first_posted>
  <last_update_submitted>October 27, 2016</last_update_submitted>
  <last_update_submitted_qc>October 27, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 31, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>David Palmer</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>brittleness</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bimatoprost</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

